Today: 14 June 2026
Browse Category

NASDAQ:DXCM 7 July 2025 - 15 May 2026

US Stock Market Today: Nasdaq Futures Slide as Oil Shock and Treasury Yields Hit Wall Street

US Stock Market Today: Nasdaq Futures Slide as Oil Shock and Treasury Yields Hit Wall Street

U.S. stock futures dropped early Friday, with Nasdaq 100 E-minis down 1.56% and S&P 500 E-minis off 1.07%, as Treasury yields and oil prices surged. Brent crude climbed to $109.19 after Donald Trump warned Iran, while the 10-year Treasury yield hit 4.54%. April retail sales rose 0.5%, dampening hopes for a Fed rate cut. Beijing summit produced no clear breakthrough on Iran.
15 May 2026
······
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom shares rose about 5% premarket Tuesday after the company reported preliminary Q4 revenue of $1.26 billion, up 13% year over year, and issued 2026 guidance above prior expectations. U.S. sales reached $892 million, with international revenue at $368 million. The company reaffirmed 2025 margin targets and raised 2026 goals. Barclays downgraded DexCom, citing competitive pressures despite strong sales.
13 January 2026
··
Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

Accenture shares climbed 4.1% to $285.18 Thursday after the company announced a new AI partnership with Profitmind and a deal to buy UK-based Faculty. The Faculty acquisition, which adds over 400 staff, aims to expand Accenture’s “safe AI” offerings. Analyst Surinder Thind raised his price target to $290. General counsel Joel Unruch sold 1,332 shares at $275 each in a prearranged trade.
8 January 2026
·····
Global Wearable Health Tech News – June and July 2025

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for remote hospital monitoring. PharmaSens and SiBionics unveiled the niia™ signature patch, combining a continuous glucose monitor and insulin pump, at ADA 2025. Fasikl’s Felix NeuroAI Wristband became the first FDA-cleared neuromodulation wearable for essential tremor. U.S. HHS Secretary RFK Jr. launched the MAHA initiative for nationwide wearable adoption.
7 July 2025
···

Stock Market Today

  • GHCL Limited to Trade Ex-Dividend on June 18 with ₹12 Dividend Payment
    June 13, 2026, 11:31 PM EDT. GHCL Limited (NSE:GHCL) will trade ex-dividend on June 18, meaning shareholders must purchase shares before this date to qualify for the upcoming dividend payout of ₹12 per share on July 25. The stock currently trades at ₹430.45, offering a trailing dividend yield of approximately 2.8%. GHCL's dividend payout ratio is conservatively low at 24% of its profit after tax and covers just 27% of its free cash flow, indicating sustainable dividend payments. Additionally, the company has demonstrated a 10% average annual growth in earnings per share over the past five years, supporting future dividend increases and business growth.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop